Addition of Rapamycin to Anti-CD3 Antibody Improves Long-Term Glycaemia Control in Diabetic NOD Mice

AIMS/HYPOTHESIS: Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing op...

Descripción completa

Detalles Bibliográficos
Autores principales: Perl, Shira, Perlman, Jordan, Weitzel, R. P., Phang, Oswald, Hsieh, Matthew M., Tisdale, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691209/
https://www.ncbi.nlm.nih.gov/pubmed/23826229
http://dx.doi.org/10.1371/journal.pone.0067189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691209/
https://www.ncbi.nlm.nih.gov/pubmed/23826229
http://dx.doi.org/10.1371/journal.pone.0067189

Ejemplares similares